share_log

Earnings Call Summary | ELSE NUTRITION HOLDINGS INC(BABYF.US) Q1 2024 Earnings Conference

Earnings Call Summary | ELSE NUTRITION HOLDINGS INC(BABYF.US) Q1 2024 Earnings Conference

财报电话会议摘要 | ELSE NUTRITION HOLDINGS INC (BABYF.US) 2024 年第一季度财报发布会
moomoo AI ·  05/19 04:45  · 电话会议

The following is a summary of the Else Nutrition Holdings Inc. (BABYF) Q1 2024 Earnings Call Transcript:

以下是Else Nutrition Holdings Inc.(BABYF)2024年第一季度财报电话会议记录摘要:

Financial Performance:

财务业绩:

  • Else Nutrition Holdings reported a Q1 2024 revenue of $2.1 million, a drop from $2.9 million in Q1 2023.

  • Despite a decrease in the quarter revenue due to anticipated customer deal delays, the company expects to see significant revenue growth throughout 2024.

  • The company saw a 92% increase in U.S. Amazon sales and a 330% increase in Canadian Amazon sales compared to the same period in 2023.

  • Else Nutrition Holdings报告称,2024年第一季度收入为210万美元,低于2023年第一季度的290万美元。

  • 尽管由于预期的客户交易延迟,本季度收入有所下降,但该公司预计2024年全年收入将大幅增长。

  • 与2023年同期相比,该公司在美国的亚马逊销售额增长了92%,加拿大亚马逊的销售额增长了330%。

Business Progress:

业务进展:

  • Else Nutrition started 2024 on a high note, with several retail partner announcements and launching their kids ready-to-drink shakes in both vanilla and chocolate flavors.

  • They are preparing to introduce an adult ready-to-drink line.

  • With the commercial launch of their plant-based infant formula in Australia, they are entering a growing market.

  • They have secured three manufacturing partners and signed a powder manufacturing agreement to guarantee supply through the end of 2025.

  • A new marketing program is underway to broaden brand recognition and fuel growth.

  • They are continually liaising with the FDA for U.S. approval based on the rising global demand for plant-based products.

  • Else Nutrition在2024年开局时表现强劲,宣布了几家零售合作伙伴,并推出了香草和巧克力口味的儿童即饮奶昔。

  • 他们正准备推出成人即饮产品线。

  • 随着其植物性婴儿配方奶粉在澳大利亚的商业推出,他们正在进入一个不断增长的市场。

  • 他们已经找到了三个制造合作伙伴,并签署了粉末制造协议,以保证2025年底之前的供应。

  • 一项新的营销计划正在进行中,以扩大品牌知名度并推动增长。

  • 鉴于全球对植物基产品的需求不断增加,他们一直在与美国食品药品管理局联络,争取美国的批准。

Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.

提示:本文由 AI 生成。无法完全保证内容的准确性。欲了解更多详情,请访问投资者关系网站。本文仅供投资者参考,不构成任何投资建议。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发